ArticleSkin appendage disorders2025
Effectiveness and Safety of Intramatricial Triamcinolone Acetonide for Trachyonychia: A Retrospective Data Analysis.
Article in Skin appendage disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Trachyonychia is a clinical presentation characterised by dry, rough, longitudinally ridged nails or opalescent shiny nail plates with pits. Intramatricial steroids are an accepted form of therapy, but efficacy data are lacking. Materials and Methods: A retrospective data analysis of 6 patients (84 nails) with trachyonychia who received treatment for at least 6 sessions, with intramatricial triamcinolone acetonide (TA) (5 mg/mL), administered at 4 weekly intervals, was conducted. Photographic records were analysed for scoring severity of disease with Nail Surface Abnormality Index (NSI) score. Endpoint of therapy was 4 weeks after the sixth injection. Results: Among the 6 patients analysed as per protocol, 4 had both finger and toenails involved, while 2 had only fingernails affected. Overall 56/60 fingernails (93.3%) and 28/60 toenails (46.6%) were affected in these patients, and were treated. The mean baseline NSI score for fingernails was 10.34 ± 4.1 (range 2-16) which improved to 6.61 ± 3.21 (range 0-12 at endpoint, showing a 37.86% reduction [ Conclusion: Intramatricial TA is a safe and effective modality for treating trachyonychia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.